A Study Evaluating FMC-376 in Participants with KRAS G12C Mutated Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors with KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid TumorMetastatic Solid TumorNon Small Cell Lung CancerColorectal CancerKRAS G12CPancreatic Cancer
- Interventions
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Frontier Medicines Corporation
- Target Recruit Count
- 403
- Registration Number
- NCT06244771
- Locations
- 🇺🇸
University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center, La Jolla, California, United States
🇺🇸University of California Irvine (UCI) - Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath